Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309979 · ClinicalTrials.gov registry record
A Study to Assess Growth in Children With Idiopathic Short Stature
A clinical trial of Idiopathic Short Stature, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT06309979 is a study of Idiopathic Short Stature that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 300 participants, above the 113-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06309979, a study of Idiopathic Short Stature, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed) - Los Angeles
- Children's Hospital of Orange County Main Campus - Orange - Orange
- Center Of Excellence in Diabetes and Endocrinology - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- University of California San Francisco (UCSF) - San Francisco
Florida
- Nemours Children's Clinic - Jacksonville
- Nicklaus Children's Hospital - Miami
- Nemours Children's Health System - Corporate Headquarters - Pensacola
Idaho
- St. Luke's Children's Endocrinology - Boise
- Rocky Mountain Diabetes Center - Idaho Falls - Idaho Falls
- Rocky Mountain Clinical Research - Idaho Falls - Idaho Falls
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale School of Medicine - New Haven
Arizona
- Phoenix Children's Hospital - Thomas Campus (Main) - Phoenix
District of Columbia
- Children's National Health System - Washington D.C.
Georgia
- Centricity Research - Columbus
Kentucky
- University of Louisville School Of Medicine - Norton Children's Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2040-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06309979
The ClinicalTrials.gov registry entry for NCT06309979 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (165% higher). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Short Stature appearing as the primary indexed condition, and to 0 interventions.
NCT06309979 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT06309979 about?
NCT06309979 is a clinical study titled "A Study to Assess Growth in Children With Idiopathic Short Stature". Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
What is the current status of trial NCT06309979?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-08-08. Estimated completion is 2040-12-31.
What conditions does trial NCT06309979 study?
This clinical trial studies the following conditions: Idiopathic Short Stature.
Who is sponsoring clinical trial NCT06309979?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309979 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Short Stature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
RECRUITING · Phase 2
-
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
RECRUITING · Phase 3
-
Genotropin Study Assessing Use of Injection Pen
COMPLETED · Phase 3
-
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.